V Pengo

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study
    A Ruffatti
    University of Padova, Padova, Italy
    Lupus 14:120-8. 2005
  2. ncbi Laboratory diagnosis of antiphospholipid syndrome
    V Pengo
    Reumatismo 59:187-91. 2007
  3. ncbi dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies
    V Pengo
    Dept of Cardiology, Thrombosis Center, University of Padova School of Medicine, Italy
    Thromb Haemost 81:256-8. 1999
  4. ncbi Effect of anti-beta2glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Italy
    Autoimmunity 32:39-44. 2000
  5. ncbi Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study
    V Pengo
    Department of Clinical and Experimental Medicine, University of Padova, Italy
    Thromb Haemost 85:418-22. 2001
  6. doi Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
    V Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    J Thromb Haemost 11:1527-31. 2013
  7. doi Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 8:237-42. 2010
  8. doi Antiphospholipid syndrome: critical analysis of the diagnostic path
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova, School of Medicine, Padova, Italy
    Lupus 19:428-31. 2010
  9. doi Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study
    G Denas
    Cardiology Clinic, Thrombosis Center, University Hospital, Via Giustiniani 2, 35128, Padua, PD, Italy
    J Thromb Thrombolysis 35:178-84. 2013
  10. ncbi Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins
    P Rampazzo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova, Italy
    Thromb Haemost 85:57-62. 2001

Collaborators

Detail Information

Publications34

  1. ncbi Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study
    A Ruffatti
    University of Padova, Padova, Italy
    Lupus 14:120-8. 2005
    ....
  2. ncbi Laboratory diagnosis of antiphospholipid syndrome
    V Pengo
    Reumatismo 59:187-91. 2007
  3. ncbi dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies
    V Pengo
    Dept of Cardiology, Thrombosis Center, University of Padova School of Medicine, Italy
    Thromb Haemost 81:256-8. 1999
    ..31 and 1.49 at a PLs dilution of 1:8 and 1:64, respectively. Therefore, the presence of LA activity due to autoantibodies to beta2-GPI is characterized by a positive dRVVT and negative or only weakly positive KCT and TTI...
  4. ncbi Effect of anti-beta2glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Italy
    Autoimmunity 32:39-44. 2000
    ..These data provide evidence that anti-beta2GPI LA may act as either anticoagulants or procoagulants in different in vitro coagulation tests...
  5. ncbi Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study
    V Pengo
    Department of Clinical and Experimental Medicine, University of Padova, Italy
    Thromb Haemost 85:418-22. 2001
    ..Patients were kept at optimal intensity of treatment for 63% of the time. These data confirm the efficacy of OA but identify elderly patients as a high risk group of major bleeding...
  6. doi Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
    V Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    J Thromb Haemost 11:1527-31. 2013
    ..Consequently, classification of patient risk and adequacy of treatment may be deferred by 3 months...
  7. doi Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 8:237-42. 2010
    ..The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described...
  8. doi Antiphospholipid syndrome: critical analysis of the diagnostic path
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova, School of Medicine, Padova, Italy
    Lupus 19:428-31. 2010
    ..Conversely, all three positive tests identify a single class of abeta2GPI antibodies, thus identifying high-risk patients with APS...
  9. doi Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study
    G Denas
    Cardiology Clinic, Thrombosis Center, University Hospital, Via Giustiniani 2, 35128, Padua, PD, Italy
    J Thromb Thrombolysis 35:178-84. 2013
    ..Any efforts to minimize these events should be pursued...
  10. ncbi Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins
    P Rampazzo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova, Italy
    Thromb Haemost 85:57-62. 2001
    ..In conclusion, some patients with APS harbor circulating antibodies to other CL-binding proteins which might be useful to further characterize these patients...
  11. doi Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA)
    V Pengo
    Clinical Cardiology, Thrombosis Center, Padova, Italy
    Thromb Haemost 106:868-76. 2011
    ..In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with...
  12. doi Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy
    A Ruffatti
    Department of Clinical and Experimental Medicine, University of Padua, Italy
    Thromb Res 123:482-7. 2009
    ..A relationship between antibody profile and pregnancy outcome in patients with a previous diagnosis of primary antiphospholipid syndrome (APS) has not been clearly documented...
  13. doi Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Via Giustiniani 2, 35128 Padova, Italy
    Thromb Haemost 103:442-9. 2010
    ..5-2.0). However, further trials are needed to confirm the hypothesis generated by the present study...
  14. doi Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, 35128 Padova, Italy
    J Thromb Haemost 7:1737-40. 2009
    ..Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations...
  15. ncbi Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, The Department of Laboratory Medicine, and the Department of Oncology and Surgical Sciences, University of Padova School of Medicine, Padova, Italy
    Blood 94:3814-9. 1999
    ..These results show that abeta2-GPI antibodies exhibit an 'in vitro' procoagulant effect in PT and an anticoagulant effect in dRVVT only when the interaction with their antigen and PL occurs in the absence of calcium ions...
  16. doi Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome
    A Banzato
    Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Italy
    Lupus 21:784-6. 2012
    ....
  17. doi Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS)
    A Banzato
    Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Via Giustiniani, 2 35128 Padova, Italy
    Thromb Res 128:583-6. 2011
    ..The relation between anti-DmI antibodies and patients' risk categories is unknown...
  18. ncbi Oral anticoagulant treatment in very elderly patients with atrial fibrillation
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata, 64 I-35128 Padova, Italy
    Compr Ther 27:7-10. 2001
    ..Therefore, a systemic approach in which the thromboembolic and hemorrhagic risk profiles are taken into account is suggested...
  19. ncbi A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Padova, Italy
    J Thromb Haemost 2:702-7. 2004
    ..Therefore, when a PL-dependent coagulation test is run twice, at different final calcium concentrations, antibeta(2)GPI LA can be identified...
  20. doi Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study
    V Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiothoracic and Vascular Sciences, University of Padova School of Medicine, Via Giustiniani 2, 35128 Padova, Italy
    Circulation 119:2920-7. 2009
    ..This prospective inception cohort management study was designed to assess the efficacy and safety of an individualized bridging protocol applied to outpatients...
  21. ncbi Anti-beta2-glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome
    V Pengo
    Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Center, University of Padua School of Medicine, Padua, Italy
    J Thromb Haemost 3:1158-9. 2005
  22. doi A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block?
    A Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Lupus 21:666-71. 2012
    ..Moreover, there was no recurrence of CHB when therapy was suspended, as confirmed by a 29 month and an eight month follow-up, respectively...
  23. ncbi Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova, School of Medicine, Padova, Italy
    J Thromb Haemost 3:433-5. 2005
  24. ncbi Long-term warfarin use to prevent both stroke and dementia in subjects with atrial fibrillation?
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Padova, Italy
    J Thromb Haemost 2:1871-2. 2004
  25. doi More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required
    A Tripodi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Cà Granda Ospedale Maggiore Policlinico Foundation and Università degli Studi di Milano, Milan Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 9:2126-7. 2011
    ..See also Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8: 2828-31...
  26. doi False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal
    A Tripodi
    Department of Internal Medicine, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Ospedale Maggiore Policlinico Foundation and Università degli Studi di Milano, Milan Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 9:1435-6. 2011
    ..False negative or false positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: reply to a rebuttal. This issue, pp 1436-7...
  27. doi A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome
    V Pengo
    J Thromb Haemost 6:1048-9. 2008
  28. ncbi Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University Hospital, Padova, Italy
    J Thromb Haemost 5:925-30. 2007
    ..To determine whether the diagnosis of lupus anticoagulant (LAC) in a large cohort of positive patients was confirmed at a reference laboratory...
  29. ncbi New trends in anticoagulant treatments
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padua School of Medicine, Padua, Italy
    Lupus 14:789-93. 2005
    ..There is no need for laboratory control, and phase II and phase III studies are encouraging. Thus, in the next few years, we may witness great changes in the treatment of patients with thromboembolic disorders...
  30. doi Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial
    M G Bousser
    Lancet 371:315-21. 2008
    ..The aim of this randomised, open-label non-inferiority trial was to compare the efficacy and safety of idraparinux with vitamin K antagonists...
  31. doi Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement
    P Marson
    J Intern Med 264:201-3. 2008
  32. ncbi Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics
    F Baudo
    Thrombosis and Hemostasis Unit, Niguarda Hospital, Milan, Italy
    Intern Emerg Med 2:280-4. 2007
    ..i.d.), the thromboembolic complications are in line with those reported in the literature. The data of this study suggest that the intervention with LMWH may be relevant only in the high-risk patients as already proposed by others...
  33. ncbi A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy
    A K Hamberg
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 81:529-38. 2007
    ..It is important to account for CYP2C9 and VKORC1 genotypes and age to improve a priori and a posteriori individualization of warfarin therapy...
  34. ncbi Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome
    Y Shoenfeld
    Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel
    J Clin Immunol 23:377-83. 2003
    ..Evaluation of APS patients for the presence of specific antipeptides Abs may be of a value in predicting the risk for future thrombotic and obstetrical complication, as well as for specific therapeutic purposes...